Keros Therapeutics (KROS) is a clinical-stage biopharmaceutical company that develops therapies for hematologic and cardiovascular disease. Wedbush’s Andreas Argyrides breaks down the biopharma space, as Wedbush has an outperform rating and an $86 price target on KROS. He also talks about Asecndis Pharma (ASND) which is on Wedbush’s top picks for 2024. He then goes over Gossamer Bio (GOSS) which is developing Seralutinib (GB002) for the treatment of PAH. Tune in to find out more about the stock market today.